Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.
Related to this article
Frontline zanubrutinib plus rituximab yielded significant efficacy improvements over SOC chemoimmunotherapy for mantle cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
2
FDA Grants Breakthrough Device Designation to Merlin CP-GEP for Early-Stage Melanoma Risk Stratification
3
SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer
4
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
5